AlphaRose has built significant value over this last quarter, with 5B+ in potential revenue waiting to be unlocked. Our team is very excited about the incredible opportunities in front of us.

To that end, we are announcing a $2m Convertible Note that just opened, Oct 1st - Nov 30th for select investors. The note is filling fast. Please reach out to me immediately if you have interest. ([email protected] / 512.940.4164)

Some significant markers:
- We are currently now advancing 5 genetic treatments in the pipeline. ($XB in potential annual revenue)
- We are continuing to develop our two proprietary RNA technologies (abcDNA and SOT Caller) poised for large licensing deals as early as 2026. (see Merck and Skyhawk as an example)
- We are in multiple discussions with potential partners in biotech, venture, and healthcare systems.
- We closed our Reg CF Round Sept 30th with $1.6M in additional investment.
- We have two non-dilutive grants we're working on totaling over $50M in potential capital.
- We have board approval to acquire RareLabs, a private genetic treatment lab in Austin, Tx, bringing in $1M in AR.

AlphaRose is poised to be a revenue generating company in 2026 and beyond, and we are excited about the impact we will be making for patients with genetic diseases for generations to come!

For more info on the note and a company update Click here: https://alpharose.info/introdeckcln2

Sincerely,

Casey McPherson and the AlphaRose Team